In this episode Dr. Gillian Beauchamp sits down with Dr. Robert "Cole" Pueringer to discuss 3 key features of fentanyl which lead to high opioid tolerance. This high opioid tolerance can lead to more severe withdrawal syndromes and difficulty with initiating buprenorphine or methadone. Rapid inpatient methadone initiation may be more effective than…

In this episode Dr. Gillian Beauchamp sits down with Dr. Benjamin Hatten to discuss the potential role of psychedelics in palliative care medicine. Specifically data that shows improved outcomes in individuals who experience psychological stress related to a terminal or life limiting illness that is refractory to more traditional treatments such as…

In this episode Dr. Gillian Beauchamp sits down with Dr. Patil Armenian to discuss strategies to promote physiologic as well as well as mental/emotional/psychiatric safety when psychedelics are used therapeutically and recreationally.

In this episode Dr. Gillian Beauchamp sits down with Dr. Laurie Halmo discuss the challenges of making informed recommendations in regard to use of substances during pregnancy.

In this episode Dr. Gillian Beauchamp sits down with Dr. John Downs to discuss recommendations for at risk occupational PFAS testing (Aviation fire fighters, certain agricultural workers (exposure to " bio sludge" , workers exposed to organofluorines, ski waxers) and challenges of generalized testing.…

In this episode Dr. Gillian Beauchamp sits down with Dr. Albert Garcia Romeu to discuss the history of psychedelic use, current treatment protocols and research on using psychedelics to support recovery from substance use disorders.

In this episode Dr. Gillian Beauchamp sits down with Dr. Michael Twiner and Dr. Brett Johnson to discuss harmful algal blooms (HABs) such as inhalation toxicity from Red Tide, neurotoxic shellfish toxicity, diarrheal shellfish poisoning, and amnestic shellfish toxicity.

In this episode Dr. Gillian Beauchamp sits down with Dr. Michael Toce to discuss naloxone access laws, increased community availability of naloxone and who still doesn't have access to naloxone. They also discuss the difference between naloxone and nalmefene and the future of nalmefene.

In this episode Dr. Gillian Beauchamp sits down with Dr. Kevin Wenzel, PhD to discuss the importance of family involvement including identifying substance use disorder, seeking treatment and providing support during treatment.

In this episode Dr. Gillian Beauchamp sits down with Jonathan Jarry MSc to discuss trends in health related pseudoscience and our role in fighting misinformation.

In this episode Dr. Gillian Beauchamp sits down with Dr. Andrew Stolbach to discuss the mechanishm of action, toxicity and management of checkpoint inhibitors (immunotherapeutic agents used in the treatment of cancer).

In this episode Dr. Gillian Beauchamp sits down with Dr. Joshua Trebach to discuss the benefits and drawbacks of utilizing social media to increase awareness and promote medical toxicology.

In this episode Dr. Gillian Beauchamp sits down with Dr. Filza Hussain to discuss transplant organ allocation in patients who have organ failure secondary to a suicide attempt.

In this episode Dr. Gillian Beauchamp sits down with Dr. Matthew Salzman discusses the complications associated with the use of illicit fentanyl containing xylazine from wounds to withdrawal.

In this episode Dr. Gillian Beauchamp sits down with Dr. Alan Wolfe to discuss the possible clinical effects of POPs (Persistent Organic Pollutants) and PFAS (Per and polyfluoroalkyl substances).

In this episode Dr. Gillian Beauchamp sits down with Dr. Travis Olives to discuss gap junctions and cardiac effects of bupropion toxicity.

In this episode Dr. Gillian Beauchamp sits down with Dr. Stephanie Weiss to discuss HERG channel blockade, QTc prolongation and cardiotoxicity.

In this episode Dr. Gillian Beauchamp sits down with Dr. Meghan Spyres to discuss the evolution of antivenom treatment of North American Pit Viper envenomation with specific discussion of the differences between Fab (CroFab) and F(ab)2 (ANAVIP) antivenom.

In this episode Dr. Gillian Beauchamp sits down with Dr. Christian Tomaszewski to discuss risk factors for delayed cardiomyopathy and mortality after carbon monoxide exposure.

In this episode Dr. Gillian Beauchamp sits down with Dr. Alex Manini to discuss single nucleotide polymorphisms (SNPs) of the Mu receptor and how they may relate to overdose severity of opioid overdose.

In this episode Dr. Gillian Beauchamp sits down with Dr. Fiona Garlich to discuss mechanisms and clinical presentations of aconitine, veratrum alkaloid and grayanotoxin cardiotoxicity.

In this episode Dr. Gillian Beauchamp sits down with Dr. Robert Haley to discuss Gulf War Illness and what caused over 100,000 people to become ill during and after the Gulf War. Dr. Haley describes the gene-environment interaction between PON-1 polymorphism and exposure to sarin gas.

In this episode Dr. Gillian Beauchamp sits down with Dr. Spencer Greene to discuss his recent case series of antimuscarninic delirium treated with rivastigmine in the setting of physostigmine shortages.

In this episode Dr. Gillian Beauchamp sits down with Dr. Tricia Wright to discuss risk factors leading to methamphetamine use disorder, associated complications in pregnancy and management of substance use disorder in pregnant and postpartum patients.

In this episode Dr. Gillian Beauchamp sits down with Dr. Tricia Wright to discuss the known and theoretical risks of cannabis use during pregnancy and lactation.

In this episode Dr. Gillian Beauchamp sits down with Dr. Mishka Terplan to discuss stigma, discrimination and prejudice in relation to substance use in pregnancy.

In this episode Dr. Gillian Beauchamp sits down with Dr. Lori Devlin to discuss Neonatal Abstinence Syndrome (NAS), Neonatal Opioid Withdrawal Syndrome (NOWS) and the treatment of NOWS.

In this episode Dr. Gillian Beauchamp sits down with Dr. Kurt Kleinschmidt to discuss the differences between dependence, addiction, and substance use disorder and how it relates to medication associated treatment (MAT).

In this episode Dr. Gillian Beuachamp sits down with Assistant Chief of Police Matthew Myers to discuss the Drug Recognition Evaluation (DRE) and the Drug Influence Evaluation (DRE) assessments.

In this episode Dr. Gillian Beauchamp sits down with Patrick Harding to discuss anterograde and retrograde ethanol calculations and how they are used in forensic toxicology.

In this episode Dr. Gillian Beauchamp sits down with Dr. Laura Tormoehlen to discuss the nuances of brain death declaration in the toxicology patient

In this episode Dr. Gillian Beauchamp sits down with Dr. Andrew Monte to discuss common nomenclature used in pharmacogenetics and pharmacogenetic factors that impact patient care in the ICU.

In this episode Dr. Gillian Beauchamp sits down with Dr. Brenna Farmer to discuss the process of gaining approval to use medications past their original expiration dates.

In this episode Dr. Gillian Beauchamp sits down with Dr. Donna Seger to discuss the clinical advantages of having a medical toxicologist at the bedside

In this episode, Dr. Gillian Beauchamp sits down with Dr. Susanna Byram to discuss the use of VV and VA ECMO and other Mechanical Circulatory Support Devices in poisoned patients.

In this episode Dr. Gillan Beauchamp sits down with Dr. Joshua King to discuss dosing adjustments of common antidotes and medications in patients undergoing HD and CCRT.

In this episode Dr. Gillian Beauchamp sits down with Dr. Zane Horowitz to discuss the challenges and strategies to provide toxicology care in remote locations.

In this episode Dr. Gillian Beauchamp sits down with Dr. Zane Horowitz to discuss the toxicity and myths of the Amanita Muscaria mushroom

In this episode Dr. Gillian Beauchamp sits down with Dr. Michael Chary to discuss the role of artificial intelligence in medical toxicology.

In this episode Dr. Gillian Beauchamp sits down with Dr. Zane Horowitz to discuss Amanita mushroom toxicity in the Northwest United States.

In this episode Dr. Gillian Beauchamp sits down with Dr. Ayrn O'Connor to discuss the clinical presentation and treatment of methamphetamine toxicity in children

In this episode Dr. Gillian Beauchamp sits down with Dr. Milky Kohno, PhD to discuss naltrexone as a treatment strategy for methamphetamine use disorder.

In this episode Dr. Gillian Beauchamp sits down with Shaun Hopkins to discuss syringe services programs (SSPs) and overdose prevention sites (OPS).

In this episode Dr. Gillian Beauchamp sits down with Dr. Bryan Judge to discuss the process of becoming a medical consulting expert.

In this episode Dr. Gillian Beauchamp sits down with Dr. Michael Lynch to discuss refractory ethanol withdrawal and the role of ketamine.

In this episode Dr. Gillian Beauchamp sits down with Dr. Daniel Sessions to discuss the potential toxicity of classic cocktails.

In this episode Dr. Gillian Beauchamp Sits down with Dr. Stephanie Weiss to discuss the chronic effects of methamphetamine and other stimulants such as cocaine on the heart.

In this episode Dr. Gillian Beauchamp sits down with Dr. Kennon Heard to discuss protein adducts in diagnosing APAP overdose

In this episode Dr. Gillian Beauchamp, MD sits down with Dr. Matthew Fedoruk, PHD to discuss the inclusion of cannabinoids on the World Anti-Doping Agency's banned substances list.

In this episode Dr. Gillian Beauchamp sits down with Dr. Jeffery Brent to discuss the use of fomepizole in acetaminophen toxicity